PARSIPPANY, N.J., Feb. 10, 2017 /PRNewswire/ -- Interpace
Diagnostics Group, Inc. (IDXG) ("Interpace" or the "Company"), a
fully integrated commercial company that provides clinically useful
molecular diagnostic tests and pathology services, today announced
that its President & Chief Executive Officer, Jack E. Stover, will deliver a corporate
presentation at the 2017 BIO CEO & Investor Conference, being
held February 13-14, 2017 at the
Waldorf Astoria Hotel in New York.
Details for this presentation are as follows:
- 2017 BIO CEO & Investor Conference – webcast available
- Time/Date: 4:30 pm ET on
Monday, February 13, 2017
- Location: Waldorf Astoria Hotel, New
York
Presentation
Room: Conrad Room
A live webcast of Interpace Diagnostics' presentation may be
accessed by logging onto the internet at
http://www.veracast.com/webcasts/bio/ceoinvestor2017/69132493167.cfm.
A replay will be archived and accessible for 90 days at the same
website.
About Interpace Diagnostics Group
Interpace is a fully integrated commercial company that provides
clinically useful molecular diagnostic tests and pathology services
for evaluating risk of cancer by leveraging the latest technology
in personalized medicine for better patient diagnosis and
management. The Company currently has three commercialized
molecular tests: PancraGEN®, for the evaluation of pancreatic cysts
and assessment of risk of concomitant or subsequent cancer;
ThyGenX®, for the diagnosis of thyroid cancer from thyroid nodules
utilizing a next generation sequencing assay; and ThyraMIR®, for
the diagnosis of thyroid cancer from thyroid nodules utilizing a
proprietary gene expression assay. Interpace's mission is to
provide personalized medicine through molecular diagnostics and
innovation to advance patient care based on rigorous science. For
more information, please visit Interpace Diagnostics' website at
www.interpacediagnostics.com.
CONTACTS:
Victor Roberts
RedChip Companies
407.644.4256, ext. 111
victor@redchip.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/interpace-diagnostics-to-present-at-2017-bio-ceo--investor-conference-300405706.html
SOURCE Interpace Diagnostics Group, Inc.